Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

7.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
Export of Misfolded Proteins out of the ER01:32

Export of Misfolded Proteins out of the ER

5.0K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-guided CRISPR screening reveals therapeutic targets in psoriasis.

Nature communications·2026
Same author

Microfluidic rare cell analysis beyond counting: workflow design from enrichment to multi-omics.

Lab on a chip·2026
Same author

Integrating Transcription Factors with Electrochemical Pendulum Bioanalysis for Hormone Detection.

Journal of the American Chemical Society·2026
Same author

Engineering Organ-on-a-Chip Systems for Cancer Immunotherapy: Strategies and Assay Integration.

Bioengineering (Basel, Switzerland)·2026
Same author

Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets.

Nature communications·2026
Same author

Resilient nanostructured bioanalytic microneedle longitudinally monitors preclinical renal and hepatic drug clearance and dysfunction.

Science translational medicine·2026

Related Experiment Video

Updated: Jan 17, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

ELOVL6 activity attenuation induces mutant KRAS degradation.

Xiyue Hu1, Ranjit Singh Atwal1,2, Sophie Xiao1

  • 1Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Nature Chemical Biology
|September 15, 2025
PubMed
Summary

Researchers identified fatty acid elongase 6 (ELOVL6) as a key target to reduce KRAS-G12V oncoprotein in cancer. This discovery paves the way for new KRAS-G12V-specific cancer therapies.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.2K

Related Experiment Videos

Last Updated: Jan 17, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • KRAS mutations are common in cancer, but targeting them is difficult due to subtle structural changes.
  • While KRAS-G12C is targeted, effective therapies for KRAS-G12V remain elusive.
  • Identifying specific vulnerabilities of KRAS-G12V is crucial for developing new cancer treatments.

Purpose of the Study:

  • To identify genes that specifically modulate the KRAS-G12V mutant.
  • To explore ELOVL6 as a potential therapeutic target for KRAS-G12V-driven cancers.
  • To understand the mechanism by which ELOVL6 affects KRAS-G12V.

Main Methods:

  • CRISPR-Cas9 genome-wide knockout screens were employed to identify modulators of KRAS-G12V.
  • Protein expression levels and oncogenic signaling pathways were analyzed.
  • Phospholipid production pathways were investigated in relation to KRAS-G12V function.

Main Results:

  • ELOVL6 was identified as a top hit, selectively reducing KRAS-G12V protein expression.
  • Targeting ELOVL6 diminished aberrant oncogenic signaling driven by KRAS-G12V.
  • ELOVL6 was found to regulate phospholipid production essential for KRAS-G12V function.

Conclusions:

  • ELOVL6 is a promising therapeutic target for KRAS-G12V-mutated cancers.
  • Targeting ELOVL6 can lead to the degradation of KRAS-G12V oncoprotein.
  • This research provides a foundation for developing novel small-molecule inhibitors against KRAS-G12V.